Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome

Award Number: R42AI132047
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/08/2017
PERIOD OF PERFORMANCE END DATE: 02/28/2026

Group Awards By:

View Award Description

A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome - PROJECT SUMMARY Rodent-borne viral outbreaks are increasing in both frequency and impact. As weather patterns evolve, rodent populations are affected and may multiply in areas where increased contact with humans results in infection. Hantaviruses, including Andes (ANDV) and Sin Nombre (SNV), are transmitted through the excreta of infected rodents and, when aerosolized, infect humans. In the Americas, hantavirus infection leads to hantavirus cardiopulmonary syndrome (HCPS), a devastating condition that features rapid onset of pulmonary edema, respiratory failure and cardiogenic shock. Treatment is supportive, not pathogen-targeted, and accordingly, approximately 40% of patients do not survive. Because hantaviruses establish lifelong, asymptomatic infections in their rodent reservoirs, they are highly prevalent in nature and represent a constant threat to humans. For example, SNV is carried by the most abundant mammal in North America, the deer mouse, which has a near ubiquitous distribution throughout the US and Canada. In the case of the South American ANDV, in addition to rodent-to-human transmission, human-to-human transmission occurs, putting not only the patient, but also family members and health care workers at risk. Despite this large potential for infection and the high case fatality rate, there are no FDA-approved treatment options or vaccines available. Hantaviruses are thus classified as NIAID Priority Pathogens and considered potential bioterrorism threats. Our long term goal is to develop an effective therapeutic against HCPS-causing hantaviruses. This proposal seeks to develop human neutralizing antibodies for therapeutic and/or prophylactic treatment of HCPS caused by ANDV. We have assembled a multidisciplinary team of molecular virologists, clinicians, and industry partners with experience developing antibody-based therapeutics. The successful development of a potent neutralizing antibody against ANDV has the potential to be a first-line antiviral for the treatment or prevention of HCPS.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	CELDARA MEDICAL, LLC	16 CAVENDISH CT STE 240	LEBANON	NH	03766	GRAFTON	USA	Allergy and Infectious Diseases Research	000	5	6/29/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $955,865 )
2025	2025	CELDARA MEDICAL, LLC	16 CAVENDISH CT STE 240	LEBANON	NH	03766	GRAFTON	USA	Allergy and Infectious Diseases Research	000	5	3/11/2025	NON-COMPETING CONTINUATION	$955,865
														Subtotal = $955,865

Issue Date FY: 2024 ( Subtotal = $993,938 )
2024	2024	CELDARA MEDICAL	16 CAVENDISH CT	LEBANON	NH	03766	GRAFTON	USA	Allergy and Infectious Diseases Research	000	4	2/22/2024	NON-COMPETING CONTINUATION	$993,938
														Subtotal = $993,938

Issue Date FY: 2023 ( Subtotal = $1,000,000 )
2023	2023	CELDARA MEDICAL, LLC	16 CAVENDISH CT	LEBANON	NH	03766	GRAFTON	USA	Allergy and Infectious Diseases Research	000	3	3/1/2023	COMPETING CONTINUATION	$1,000,000
														Subtotal = $1,000,000

Grand Total All Awards = $2,949,803

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome

Award Number: R42AI132047

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/08/2017

PERIOD OF PERFORMANCE END DATE: 02/28/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer